Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
Biotronik, Inc. · Decision date Sep 25, 2026
What did the FDA approve?
The supplied record shows FDA decision APPR on 2026-09-25 for supplement S172 to PMA P070008, filed by Biotronik, Inc. under product code NKE, implantable CRT-P pulse generator. The supplement is on the Normal 180 Day Track, with the stated reason "Change Design/Components/Specifications/Material." Because the identifier P070008 ties this supplement to the original PMA, it is a change to that approved device, not a new approval of the whole system.
The only stated purpose is "the next generation of the Home Monitoring Service Center (HMSC)." The record does not specify which design, component, specification or material changed, nor how HMSC relates to the listed CRT-P generators, so those details are absent. The purpose statement is a reported intent, not independent proof of safety or clinical effectiveness, and the record carries no new indication or trial information.
The decision field shows APPR with no stated approval order or conditions. Device category, specialty and applicant come from the database fields; the record does not identify manufacturing sites or the supplement's document contents.
FDA approval order statement
the next generation of the Home Monitoring Service Center (HMSC)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P070008/S172
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- Decision code
- APPR
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P070008. Subsequent supplements may change the device or its indications.
FDA decision timeline
P070008 · Original PMA
STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD
P070008/S172 received
Application receipt date recorded by FDA.
P070008/S179 · Related supplement
PSW 2601.U, NEO 2601.U
P070008/S172 · FDA decision
Normal 180 Day Track
P070008/S182 · Related supplement
Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-
P070008/S181 · Related supplement
Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr
P070008/S183 · Related supplement
Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T
P070008/S177 · Related supplement
BIOexpress
P070008/S184 · Related supplement
Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR
Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | May 12, 2008 | FDA | |
PSW 2601.U, NEO 2601.UP070008/S179 | Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA | |
| Guidant Corp. | PMA approval | Jan 26, 2004 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P070008/S172
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



